Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.
Four patients with human-immuno-deficiency-virus-associated neurological disease were treated with 3'-azido-3'-deoxythymidine (AZT). Three (two with chronic dementia, and one with chronic dementia and peripheral neuropathy) improved as assessed by clinical examination, psychometric tests, nerve conduction studies, and/or positron emission tomography; there was no improvement in the fourth patient who presented with paraplegia. These results support the hypothesis that certain AIDS-virus-associated neurological abnormalities are reversible by antiretroviral chemotherapy.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D001927:Brain Diseases / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000188:drug therapy*; D013936:Thymidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015215:Zidovudine
D015215:Zidovudine; D013936:Thymidine